Bevacizumab Treatment and Retinal Vessel Monitoring (BevaRet)

Technische Universität Dresden

Status: Completed

Conditions: Cancer

Treatments: Drug: bevacizumab treatment

Study type: Observational

Funder types: Other

Identifiers

NCT00740168

B-ANF1

Details and patient eligibility

About

Bevacizumab might influence the dynamic vessel function after being administered intravenously.

Full description

By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who wish and need bevacizumab treatment for underlying disease

Exclusion criteria

• previous bevacizumab treatment
• known eye disease, eye surgery or eye trauma in history
• myopia >-2.0 dpt
• hyperopia > +2.0 dpt.
• relevant media opacity of the lens
• acute heart disease, ischemic insult, proven coronary heart disease
• cardiac arrhythmia or vessel anomalies
• seizure disorder or episode in history
• migraine
• treatment with corticosteroids within 4 weeks before study inclusion
• intake of vasoactive drugs like AT-1 or glitazone
• pregnancy

Trial design

20 participants in 1 patient group

TG

Description:

Bevacizumab treatment group with metastasized cancer

Treatment:

Drug: bevacizumab treatment